Compositions and methods of improved wound healing
AssigneeChan Soon-Shiong Nanthealth Foundation
InventorsKayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Oleksandr Buzko, Anne-Laure Le Ny, Patrick Soon-Shiong
Life of this patent
Estimating the term…
Abstract
Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
Claims14
A method of improving healing of a sterile or toll-like receptor (TLR)/nucleotide-binding oligomerization domain receptor (NOD) ligand-poor wound, comprising:
- administering a Ca2+-flux agonist (CFA) at a concentration and a pattern recognition receptor (PRR) ligand to a patient under a protocol that ensures presence of at least a portion of the CFA and at least a portion of the PRR ligand at the wound;
- wherein the concentration of CFA is below an amount providing the maximum response obtainable with the CFA in the absence of the PRR ligand;
- wherein the portion of the CFA and the portion of the PRR ligand are present in the wound in an amount effective to improve healing of the wound;
- wherein the PRR ligand is selected from the group consisting of Pam2CSK4, Pam2CYS, PAM2, ODN2006, lipopolysaccharide, C12iE-DAP, flagellin, and muramyl dipeptide;
- and
- wherein the CFA is thapsigargin.
A method of treating a sterile or TLR/NOD ligand-poor wound, comprising:
- administering to the wound a pattern recognition receptor (PRR) ligand to produce at the wound site a non-saturating stimulus for a TLR and/or NOD signaling pathway;
- administering to the wound a Ca2+-flux agonist (CFA) in an amount effective to amplify the stimulus;
- wherein amplification of the stimulus is performed under a protocol that improves healing of the wound;
- wherein the PRR ligand is Pam2CYS;
- and
- wherein the CFA is thapsigargin.
A method of improving healing of a sterile or toll-like receptor (TLR)/nucleotide-binding oligomerization domain receptor (NOD) ligand-poor wound, comprising:
- administering a Ca2+-flux agonist (CFA) at a concentration and a pattern recognition receptor (PRR) ligand to a patient under a protocol that ensures presence of at least a portion of the CFA and at least a portion of the PRR ligand at the wound;
- wherein the concentration of CFA is below an amount providing the maximum response obtainable with the CFA in the absence of the PRR ligand;
- wherein the portion of the CFA and the portion of the PRR ligand are present in the wound in an amount effective to improve healing of the wound;
- wherein the PRR ligand is Pam2CYS;
- and
- wherein the CFA is selected from the group consisting of ionomycin, calcimycin, cyclopiazonic acid (CPA), 2,5-di-tert-butylhydroquinone (DBHQ), or thapsigargin.
Dependencies are inferred from the claim text.